Company Description
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons.
In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation.
Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery.
Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
| Country | Australia |
| Founded | 1989 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Simon Morriss |
Contact Details
Address: 60-66 Hanover Street Fitzroy, Victoria, C3 3065 Australia | |
| Phone | 011613-9415-1135 |
| Website | gtglabs.com |
Stock Details
| Ticker Symbol | GENE |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| CIK Code | 0001166272 |
| CUSIP Number | 37185R208 |
| ISIN Number | US37185R4065 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kevin Camilleri | Chief Executive Officer of EasyDNA |
| Simon Morriss | Chief Executive Officer |
| Carl S. Stubbings BSc | Chief Commercial Officer |
| Kathryn J. E. Andrews B.Com, CPA | Chief Financial Officer and Company Secretary |
| Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | 6-K | Report of foreign issuer |
| Jun 28, 2024 | 6-K | Report of foreign issuer |
| Jun 21, 2024 | 6-K | Report of foreign issuer |
| Jun 5, 2024 | 6-K | Report of foreign issuer |
| May 29, 2024 | 6-K | Report of foreign issuer |
| May 24, 2024 | EFFECT | Notice of Effectiveness |
| May 21, 2024 | UPLOAD | Filing |
| May 20, 2024 | F-1 | Registration statement for certain foreign private issuers |
| May 6, 2024 | 6-K | Report of foreign issuer |
| Apr 30, 2024 | 6-K | Report of foreign issuer |